Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection

NCT04966663 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04966663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
March 28, 2022
Completion date
December 1, 2026
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor dna, complete surgical resection, non small cell lung cancer